explore -WSS

explore

author：Wikipedia 2025-09-27 17:35:32 Page View：72655

STAT Q&A — Paul Matteis (right), in 2017 with then-colleagues Seamus Fernandez (far left) Geoffrey Porges. Alex Hogan/STAT

NEW YORK — Is biotech having a renaissance in neuroscience? Can we solve the placebo effect? And what’s going to happen next year?

Paul Matteis, co-head of biotech research at Stifel, sat down with STAT at the firm’s annual health care conference here to field those questions and opine on how management teams can walk the delicate balance between hype and sandbagging. This transcript has been edited for length and clarity.

One thing I’ve been hearing lately is that biotech has entered a sort of renaissance in neuroscience. Do you agree with that?

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Americans' trust in science, scientist continues decline: Report
Next article： Activists slam private health insurers over coverage restrictions

focus

Activists slam private health insurers over coverage restrictions

ProtestorsoutsideAmerica'sHealthInsurancePlansheadquarters.CourtesyPeople'sActionWASHINGTON—Hun

Christmas in the PICU brings some surprising joy

Calsmilesonher8thbirthday,justbeforeChristmas,afterbeingextubated.CourtesyMariaKefalasInthedaysleadi

How one medical school became remarkably diverse

ThefirstclassattheUniversityofCalifornia,Davismedicalschool,in1972,waspredominantlywhiteandmale.Chri

The woman behind the Dana Farber

LaurieGlimcher,CEOofDanaFarberCancerInstitute,isthearchitectofthebiggestshakeupinBostonhealthcareind